BDBM361984 US10221182, Compound C-1.1::US10221182, Compound E1-1.12

SMILES FC1(F)CN(CCc2ccccc2)CCC1Nc1ncnc2[nH]ncc12

InChI Key InChIKey=WHBAEJDKYDGMTF-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 361984   

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 83.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 83.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 98.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 98.8nMAssay Description:HEK293 cell lines stably expressing cloned human NR1/NR2B and NR1/NR2A, respectively, were established according to standard previously described met...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 1.00E+4nMAssay Description:TBDMore data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Rugen Holdings (Cayman)

US Patent
LigandPNGBDBM361984(US10221182, Compound E1-1.12 | US10221182, Compoun...)
Affinity DataIC50: 7.10E+4nMAssay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/27/2019
Entry Details
US Patent